NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
IOLCP Expands Ethyl Acetate and Acetic Anhydride Capacities via Rs 9.71 Cr Capex
IOL Chemicals and Pharmaceuticals Limited has successfully completed the expansion of its manufacturing facilities for Ethyl Acetate and Acetic Anhydride as of March 2, 2026. The Ethyl Acetate capacity has been increased by 20,000 MTPA to reach 1,20,000 MTPA, while Acetic Anhydride capacity grew by 7,000 MTPA to 32,000 MTPA. The total project cost of Rs 9.71 crore was entirely funded through internal accruals, indicating a healthy balance sheet. This expansion is strategically timed as existing facilities were operating at 90-100% utilization.
முக்கிய அம்சங்கள்
Ethyl Acetate capacity increased from 1,00,000 MTPA to 1,20,000 MTPA (20% increase)Acetic Anhydride capacity enhanced from 25,000 MTPA to 32,000 MTPA (28% increase)Total capital expenditure of Rs 9.71 crore funded through internal accrualsExpansion completed on March 2, 2026, to address high utilization rates and market demandAims to improve margin realization through optimum operating leverage
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive growth signal as the company is expanding capacity in segments where it already has high utilization. The use of internal accruals for capex further strengthens the investment case by avoiding additional debt.
IOLCP Secures EDQM CEP Certification for Clopidogrel Besilate API
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product, Clopidogrel Besilate. This certification, issued on February 23, 2026, serves as a significant regulatory milestone for the company's cardiovascular portfolio. IOLCP already maintains a valid CEP for Clopidogrel Bisulphate, and this new addition expands its product range for the European market. The approval is expected to strengthen the company's position as a key supplier of antiplatelet medications globally.
முக்கிய அம்சங்கள்
EDQM issued the CEP for Clopidogrel Besilate on February 23, 2026, following strict quality standards.The company now holds CEPs for two variants: Clopidogrel Besilate and Clopidogrel Bisulphate.Clopidogrel is an essential antiplatelet medication used for treating and preventing cardiovascular diseases.This regulatory approval facilitates easier market access and compliance for IOLCP's API exports to Europe.
👀 கவனிக்க வேண்டியவை
This approval strengthens IOLCP's export portfolio and validates its manufacturing quality standards; investors should maintain a positive outlook on the company's API business growth.
IOLCP Q3 FY26 Revenue Up 11% to ₹580 Cr; EBITDA Grows 23% with 10.7% Margin
IOL Chemicals and Pharmaceuticals reported a resilient Q3 FY26 with revenue growing 10.9% YoY to ₹580 crores and EBITDA rising 22.8% to ₹62.6 crores. The company's diversification strategy is yielding results, with non-ibuprofen APIs now contributing ₹128 crores to the pharmaceutical segment. Despite persistent high fuel costs in Punjab, management expects a 1-2% margin improvement in Q4 FY26. The board declared a 50% interim dividend, and the company maintains a positive growth guidance of 10-15% for FY27.
முக்கிய அம்சங்கள்
Revenue from operations increased 10.9% YoY to ₹580 crores, while EBITDA grew 22.8% to ₹62.6 crores.Non-ibuprofen API portfolio contributed ₹128 crores, reflecting successful diversification away from core ibuprofen products.Capacity utilization remains robust with Ibuprofen at 90-95% and the Chemicals division at nearly 100%.Management guided for 10-15% top-line and 15-20% bottom-line growth in FY27, supported by ₹150-200 crore annual capex.Reported a non-recurring exceptional item of ₹11.2 crores pertaining to new labor law provisions.
👀 கவனிக்க வேண்டியவை
Investors should focus on the improving product mix and the ramp-up in paracetamol capacity as key growth drivers. The stock remains a solid play on API diversification and backward integration efficiencies.
IOLCP Declares Rs 1 Interim Dividend; Sets Feb 17 as Record Date for FY 2025-26
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has declared an interim dividend of Rs 1 per equity share, representing 50% of the face value of Rs 2, for the financial year 2025-26. The company has designated February 17, 2026, as the record date to identify eligible shareholders for this payout. Detailed guidelines for Tax Deduction at Source (TDS) have been issued, including a 20% deduction rate for accounts without a valid or linked PAN. Resident individual shareholders are exempt from TDS if their total dividend income from the company does not exceed Rs 10,000 during the fiscal year.
முக்கிய அம்சங்கள்
Interim dividend of Rs 1 per share (50% of face value) declared for FY 2025-26Record date for dividend entitlement is fixed for February 17, 2026TDS of 20% applicable for shareholders with invalid or non-Aadhaar linked PANExemption from TDS for resident individuals if total dividend is below Rs 10,000Deadline for submitting tax exemption forms (15G/15H) is February 17, 2026
👀 கவனிக்க வேண்டியவை
Investors should ensure their PAN is correctly linked and bank details are updated in their demat accounts before the record date. Eligible shareholders should submit Form 15G/15H through the Alankit Assignments portal by February 17 to avoid unnecessary tax deductions.
IOLCP Q3 FY26 Results: EBITDA Grows 22.8% YoY to ₹62.6 Cr; Revenue Up 10.9%
IOL Chemicals and Pharmaceuticals Limited (IOLCP) reported a steady Q3 FY26 performance with revenue growing 10.9% YoY to ₹580.4 Cr. EBITDA margins improved to 10.7% from 9.7% YoY, while PBT before exceptional items surged 39.3% to ₹38.8 Cr. The bottom line was slightly impacted by an exceptional charge of ₹11.2 Cr related to new labour code provisions. The company is successfully diversifying its portfolio, with the non-Ibuprofen segment now contributing significantly to growth.
முக்கிய அம்சங்கள்
Revenue from operations increased 10.9% YoY to ₹580.4 Cr in Q3 FY26.EBITDA grew 22.8% YoY to ₹62.6 Cr with margins expanding by 100 bps to 10.7%.PBT before exceptional items rose 39.3% YoY to ₹38.8 Cr.Commenced New Unit 11 for Paracetamol with a significant installed capacity of 10,800 MTPA.Maintains a very strong financial position with a Debt-to-Equity ratio of 0.07.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful transition from an Ibuprofen-heavy player to a diversified API manufacturer. The massive expansion in Paracetamol capacity and low leverage provide a strong foundation for long-term growth.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
IOLCP Q3 FY26 Results: PBT Jumps 39.3% YoY to ₹38.8 Cr; Pharma Revenue Up 18%
IOL Chemicals and Pharmaceuticals (IOLCP) reported a robust Q3 FY26 performance with revenue growing 10.9% YoY to ₹580.4 crore. Profit Before Tax (before exceptional items) surged by 39.3% YoY to ₹38.8 crore, supported by a 102 bps expansion in EBITDA margins to 10.7%. The growth was largely driven by the Pharmaceuticals segment, which saw an 18% revenue increase and now accounts for 61% of the total revenue mix, up from 57% last year.
முக்கிய அம்சங்கள்
Revenue from operations increased 10.9% YoY to ₹580.4 Cr in Q3 FY26.PBT (before exceptional items) grew 39.3% YoY to ₹38.8 Cr with a margin of 6.6%.Pharmaceuticals segment EBIT rose 32% YoY to ₹34.5 Cr, driven by non-Ibuprofen APIs.Chemicals segment EBIT grew 37% YoY to ₹6.5 Cr despite flat revenue growth.9M FY26 EBITDA stands at ₹196.1 Cr, up 24.8% compared to the previous year.
👀 கவனிக்க வேண்டியவை
Investors should note the positive shift in product mix towards the higher-margin Pharmaceutical segment and the successful diversification into non-Ibuprofen APIs. The consistent margin expansion over the nine-month period suggests strong operational efficiency and resilience against global headwinds.
IOLCP Reports Q3 Revenue Growth of 11% YoY and Declares ₹1 Interim Dividend
IOL Chemicals and Pharmaceuticals (IOLCP) reported a 10.9% YoY increase in Q3 FY26 revenue to ₹580.39 crore. The company declared an interim dividend of ₹1 per share (50% of face value) with a record date of February 17, 2026. Net profit for the quarter remained flat at ₹20.58 crore, primarily due to an exceptional item of ₹11.21 crore. However, the nine-month performance remains strong with PAT rising 21.8% to ₹84.54 crore compared to the previous year.
முக்கிய அம்சங்கள்
Declared an interim dividend of ₹1 per equity share (50% of FV ₹2) with Record Date as Feb 17, 2026.Q3 Revenue from operations increased by 10.9% YoY to ₹580.39 crore from ₹523.30 crore.Nine-month (9M FY26) Net Profit grew by 21.8% to ₹84.54 crore from ₹69.38 crore YoY.Pharmaceutical segment revenue grew to ₹356.05 crore in Q3, up from ₹300.58 crore in the same quarter last year.Reported an exceptional item of ₹11.21 crore during the quarter, which impacted the quarterly profit before tax.
👀 கவனிக்க வேண்டியவை
Investors should note the record date of February 17 for dividend eligibility. The steady revenue growth in the pharmaceutical segment is a positive indicator for long-term growth despite the quarterly impact of exceptional items.
IOL Chemicals and Pharmaceuticals Limited has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product "MINOXIDIL" on December 4th, 2025. Minoxidil is used for treating hereditary hair loss. This certification indicates that IOLCP's Minoxidil meets European quality standards, potentially opening up new markets and increasing export opportunities. This regulatory approval can positively impact the company's revenue from API sales.
முக்கிய அம்சங்கள்
EDQM granted CEP Certificate for MINOXIDIL on December 4th, 2025MINOXIDIL is used as a topical treatment for hereditary hair lossCertificate issued by the European Directorate for the Quality of Medicines & Health Care (EDQM)
👀 கவனிக்க வேண்டியவை
Investors should monitor IOLCP's sales and revenue growth in the coming quarters to assess the financial impact of this certification. Keep an eye on further regulatory approvals in other geographies.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
